Tip 2 Diyabet ve Obezite Yönetiminde GLP-1 Temelli Tedaviler ve Tıbbi Beslenme Tedavisi

Kaynaklar

American Diabetes Association (2025a). 5. Facilitating positive health behaviors and well-being to improve health outcomes: Standards of Care in Diabetes—2025. Diabetes care, 48(Supplement_1), S86-S127.

American Diabetes Association (2025b). 8. Obesity and Weight Management for the Prevention and Treatment of Diabetes: Standards of Care in Diabetes–2026. Diabetes care, 49(Supplement_1), S166-S182. https://doi.org/10.2337/dc26-S008

Almandoz, J. P., Wadden, T. A., Tewksbury, C., Apovian, C. M., Fitch, A., Ard, J. D., Li, Z., Richards, J., Butsch, W. S., & Jouravskaya, I. (2024). Nutritional considerations with antiobesity medications. Obesity, 32(9), 1613-1631.

Aronne, L. J., Horn, D. B., le Roux, C. W., Ho, W., Falcon, B. L., Gomez Valderas, E., Das, S., Lee, C. J., Glass, L. C., Senyucel, C., & Dunn, J. P. (2025). Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. N Engl J Med, 393(1), 26-36. https://doi.org/10.1056/NEJMoa2416394

Barrea, L., Annunziata, G., Verde, L., Galasso, M., Savastano, S., Colao, A., & Muscogiuri, G. (2025). A Multidisciplinary Perspective on Semaglutide Treatment and Medical Nutrition Therapy in Obesity Management. Current Obesity Reports, 14(1), 73. https://doi.org/10.1007/s13679-025-00667-3

Chandrasekaran, P., & Weiskirchen, R. (2024). The Role of Obesity in Type 2 Diabetes Mellitus-An Overview. Int J Mol Sci, 25(3). https://doi.org/10.3390/ijms25031882

Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., & Lingvay, I. (2021). Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet, 397(10278), 971-984. https://doi.org/10.1016/s0140-6736(21)00213-0

Davies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., & Mingrone, G. (2022). Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia, 65(12), 1925-1966. https://doi.org/10.1007/s00125-022-05787-2

Eisa, N., & Barood, O. (2026). Lean Mass Changes With Incretin Therapy Versus Lifestyle Intervention: A Systematic Review and Meta-Analysis of Randomised Controlled Trials. Diabetes Obes Metab, 28(6), 4818-4827. https://doi.org/10.1111/dom.70666

Esposito, K., Maiorino, M. I., Bellastella, G., Chiodini, P., Panagiotakos, D., & Giugliano, D. (2015). A journey into a Mediterranean diet and type 2 diabetes: a systematic review with meta-analyses. BMJ open, 5(8), e008222.

Evert, A. B., & Boucher, J. L. (2014). New Diabetes Nutrition Therapy Recommendations: What You Need to Know. Diabetes Spectr, 27(2), 121-130. https://doi.org/10.2337/diaspect.27.2.121

Fineman, M. S., Cirincione, B. B., Maggs, D., & Diamant, M. (2012). GLP-1 based therapies: differential effects on fasting and postprandial glucose. Diabetes Obes Metab, 14(8), 675-688. https://doi.org/10.1111/j.1463-1326.2012.01560.x

Fitch, A., Gigliotti, L., & Bays, H. E. (2025). Application of nutrition interventions with GLP-1 based therapies: A narrative review of the challenges and solutions. Obes Pillars, 16, 100205. https://doi.org/10.1016/j.obpill.2025.100205

Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med, 385(6), 503-515. https://doi.org/10.1056/NEJMoa2107519

Garvey, W. T., Frias, J. P., Jastreboff, A. M., le Roux, C. W., Sattar, N., Aizenberg, D., Mao, H., Zhang, S., Ahmad, N. N., Bunck, M. C., Benabbad, I., & Zhang, X. M. (2023). Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet, 402(10402), 613-626. https://doi.org/10.1016/s0140-6736(23)01200-x

Gentinetta, S., Sottotetti, F., Manuelli, M., & Cena, H. (2024). Dietary Recommendations for the Management of Gastrointestinal Symptoms in Patients Treated with GLP-1 Receptor Agonist. Diabetes Metab Syndr Obes, 17, 4817-4824. https://doi.org/10.2147/dmso.S494919

Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Riesmeyer, J. S., Riddle, M. C., Rydén, L., Xavier, D., Atisso, C. M., Dyal, L., Hall, S., Rao-Melacini, P., Wong, G., Avezum, A., Basile, J., Chung, N.,…Zigrang, W. (2019). Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. The Lancet, 394(10193), 121-130. https://doi.org/10.1016/S0140-6736(19)31149-3

Grosicki, G. J., Dhurandhar, N. V., Unick, J. L., Arent, S. M., Thomas, J. G., Lofton, H., Shepherd, M. C., Kiel, J., Coleman, C., & Jonnalagadda, S. S. (2024). Sculpting Success: The Importance of Diet and Physical Activity to Support Skeletal Muscle Health during Weight Loss with New Generation Anti-Obesity Medications. Curr Dev Nutr, 8(11), 104486. https://doi.org/10.1016/j.cdnut.2024.104486

Heise, T., DeVries, J. H., Urva, S., Li, J., Pratt, E. J., Thomas, M. K., Mather, K. J., Karanikas, C. A., Dunn, J., Haupt, A., Milicevic, Z., & Coskun, T. (2023). Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes. Diabetes care, 46(5), 998-1004. https://doi.org/10.2337/dc22-1710

Herron, E., Cencetti, J., & Matis, J. (2024). Reducing or discontinuing insulin or sulfonylurea when initiating a glucagon-like peptide-1 agonist. Federal Practitioner, 41(2), 52. 10.12788/fp.0452

Heymsfield, S. B., Yang, S., McCarthy, C., Brown, J. B., Martin, C. K., Redman, L. M., Ravussin, E., Shen, W., Müller, M. J., & Bosy-Westphal, A. (2024). Proportion of caloric restriction-induced weight loss as skeletal muscle. Obesity (Silver Spring), 32(1), 32-40. https://doi.org/10.1002/oby.23910

Hjerpsted, J. B., Flint, A., Brooks, A., Axelsen, M. B., Kvist, T., & Blundell, J. (2018). Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity. Diabetes Obes Metab, 20(3), 610-619. https://doi.org/10.1111/dom.13120

Imamura, F., Micha, R., Wu, J. H., de Oliveira Otto, M. C., Otite, F. O., Abioye, A. I., & Mozaffarian, D. (2016). Effects of Saturated Fat, Polyunsaturated Fat, Monounsaturated Fat, and Carbohydrate on Glucose-Insulin Homeostasis: A Systematic Review and Meta-analysis of Randomised Controlled Feeding Trials. PLoS Med, 13(7), e1002087. https://doi.org/10.1371/journal.pmed.1002087

International Diabetes Fedaration. (2021). Diabetes Atlas 10th edition. Report no. 10. https://diabetesatlas.org/atlas/tenth-edition/

Jastreboff, A. M., Kaplan, L. M., Frías, J. P., Wu, Q., Du, Y., Gurbuz, S., Coskun, T., Haupt, A., Milicevic, Z., & Hartman, M. L. (2023). Triple–hormone-receptor agonist retatrutide for obesity—a phase 2 trial. New England Journal of Medicine, 389(6), 514-526.

Jastreboff, A. M., le Roux, C. W., Stefanski, A., Aronne, L. J., Halpern, B., Wharton, S., Wilding, J. P., Perreault, L., Zhang, S., & Battula, R. (2025). Tirzepatide for obesity treatment and diabetes prevention. New England Journal of Medicine, 392(10), 958-971.

Karakasis, P., Patoulias, D., Fragakis, N., & Mantzoros, C. S. (2025). Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: Systematic review and network meta-analysis. Metabolism, 164, 156113. https://doi.org/https://doi.org/10.1016/j.metabol.2024.156113

Latif, W., Lambrinos, K. J., & Rodriguez, R. (2021). Compare and contrast the glucagon-like peptide-1 receptor agonists (GLP1RAs).

Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., Lingvay, I., Oral, T. K., Michelsen, M. M., Plutzky, J., Tornøe, C. W., & Ryan, D. H. (2023). Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med, 389(24), 2221-2232. https://doi.org/10.1056/NEJMoa2307563

Liu, L., Mei, M., Yang, S., & Li, Q. (2014). Roles of chronic low‐grade inflammation in the development of ectopic fat deposition. Mediators of inflammation, 2014(1), 418185.

Lomeli, L. D., Kodali, A. M., Tsushima, Y., Mehta, A. E., & Pantalone, K. M. (2024). The incidence of acute pancreatitis with GLP-1 receptor agonist therapy in individuals with a known history of pancreatitis. Diabetes Res Clin Pract, 215, 111806. https://doi.org/10.1016/j.diabres.2024.111806

Lu, X., Xie, Q., Pan, X., Zhang, R., Zhang, X., Peng, G., Zhang, Y., Shen, S., & Tong, N. (2024). Type 2 diabetes mellitus in adults: pathogenesis, prevention and therapy. Signal transduction and targeted therapy, 9(1), 262.

Lundgren, J. R., Janus, C., Jensen, S. B., Juhl, C. R., Olsen, L. M., Christensen, R. M., Svane, M. S., Bandholm, T., Bojsen-Møller, K. N., & Blond, M. B. (2021). Healthy weight loss maintenance with exercise, liraglutide, or both combined. New England Journal of Medicine, 384(18), 1719-1730.

Maldonado, J. M., De Block, C., Frias, J. P., Lee, C., Brown, K., Wang, H., & Thomas, M. K. (2023). 771-P: Tirzepatide Reduces HbA1c and Body Weight Significantly More than Placebo or Semaglutide Irrespective of Baseline Beta-Cell Function—Post Hoc Analysis from SURPASS-1 and SURPASS-2. Diabetes, 72(Supplement_1). https://doi.org/10.2337/db23-771-P

Marshall, S., Ryan, E., Rivera, J., Reynolds, L., & Atti, S. (2024). GLP-1 Receptor Agonist Exposures Are Increasingly Common and Generally Associated with Mild Symptoms: A Single Poison Center Experience. J Med Toxicol, 20(3), 278-285. https://doi.org/10.1007/s13181-024-01008-x

Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., & Warren, M. L. (2016). Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. New England Journal of Medicine, 375(19), 1834-1844.

Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., Woo, V., Hansen, O., Holst, A. G., Pettersson, J., & Vilsbøll, T. (2016). Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med, 375(19), 1834-1844. https://doi.org/10.1056/NEJMoa1607141

Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., Steinberg, W. M., Stockner, M., Zinman, B., Bergenstal, R. M., & Buse, J. B. (2016). Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med, 375(4), 311-322. https://doi.org/10.1056/NEJMoa1603827

Mehrtash, F., Dushay, J., & Manson, J. E. (2025). Integrating Diet and Physical Activity When Prescribing GLP-1s—Lifestyle Factors Remain Crucial. JAMA Internal Medicine, 185(9), 1151-1152. https://doi.org/10.1001/jamainternmed.2025.1794

Min, J. S., Jo, S. J., Lee, S., Kim, D. Y., Kim, D. H., Lee, C. B., & Bae, S. K. (2025). A Comprehensive Review on the Pharmacokinetics and Drug-Drug Interactions of Approved GLP-1 Receptor Agonists and a Dual GLP-1/GIP Receptor Agonist. Drug Des Devel Ther, 19, 3509-3537. https://doi.org/10.2147/dddt.S506957

Müller, T. D., Finan, B., Bloom, S., D'Alessio, D., Drucker, D. J., Flatt, P., Fritsche, A., Gribble, F., Grill, H., & Habener, J. (2019). Glucagon-like peptide 1 (GLP-1). Molecular metabolism, 30, 72-130.

Perkovic, V., Tuttle, K. R., Rossing, P., Mahaffey, K. W., Mann, J. F. E., Bakris, G., Baeres, F. M. M., Idorn, T., Bosch-Traberg, H., Lausvig, N. L., & Pratley, R. (2024). Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med, 391(2), 109-121. https://doi.org/10.1056/NEJMoa2403347

Prado, C. M., Phillips, S. M., Gonzalez, M. C., & Heymsfield, S. B. (2024). Muscle matters: the effects of medically induced weight loss on skeletal muscle. Lancet Diabetes Endocrinol, 12(11), 785-787. https://doi.org/10.1016/s2213-8587(24)00272-9

Quarenghi, M., Capelli, S., Galligani, G., Giana, A., Preatoni, G., & Turri Quarenghi, R. (2025). Weight Regain After Liraglutide, Semaglutide or Tirzepatide Interruption: A Narrative Review of Randomized Studies. J Clin Med, 14(11). https://doi.org/10.3390/jcm14113791

Reynolds, A., & Mitri, J. (2024). Dietary advice for individuals with diabetes. Endotext [Internet].

Samson, S. L., Vellanki, P., Blonde, L., Hirsch, I. B., Hoang, T. D., Isaacs, S. D., Izuora, K. E., Low Wang, C. C., Ooi, C. P., Padilla, B. I., Schulman-Rosenbaum, R., Twining, C. L., Umpierrez, G. E., & Valencia, W. M. (2026). American Association of Clinical Endocrinology Consensus Statement: Algorithm for Management of Adults With Type 2 Diabetes - 2026 Update. Endocr Pract, 32(4), 473-518. https://doi.org/10.1016/j.eprac.2026.01.006

Satman, I., Omer, B., Tutuncu, Y., Kalaca, S., Gedik, S., Dinccag, N., Karsidag, K., Genc, S., Telci, A., & Canbaz, B. (2013). Twelve-year trends in the prevalence and risk factors of diabetes and prediabetes in Turkish adults. European journal of epidemiology, 28(2), 169-180.

Satman, I., Yilmaz, T., Sengul, A., Salman, S., Salman, F., Uygur, S., Bastar, I., Tütüncü, Y., Sargin, M., & Dinççag, N. (2002). Population-based study of diabetes and risk characteristics in Turkey: results of the turkish diabetes epidemiology study (TURDEP). Diabetes care, 25(9), 1551-1556.

Schneck, K., & Urva, S. (2024). Population pharmacokinetics of the GIP/GLP receptor agonist tirzepatide. CPT Pharmacometrics Syst Pharmacol, 13(3), 494-503. https://doi.org/10.1002/psp4.13099

Sisson, E. M. (2011). Liraglutide: clinical pharmacology and considerations for therapy. Pharmacotherapy, 31(9), 896-911. https://doi.org/10.1592/phco.31.9.896

Uccellatore, A., Genovese, S., Dicembrini, I., Mannucci, E., & Ceriello, A. (2015). Comparison Review of Short-Acting and Long-Acting Glucagon-like Peptide-1 Receptor Agonists. Diabetes Ther, 6(3), 239-256. https://doi.org/10.1007/s13300-015-0127-x

Türkiye İstatistik Kurumu (2023). Türkiye Sağlık Araştırması 2022. Ankara.

Türkiye Beslenme Rehberi, TÜBER (2022). Sağlık Bakanlığı, Yayın No:1031,. Ankara. https://hsgm.saglik.gov.tr/tr/web-uygulamalarimiz/357.html

Türkiye Diyabet ve Metabolizma Derneği. (2024). Diabetes Mellitus Ve Komplikasyonlarinin Tani, Tedavi Ve İzlem Kilavuzu.

Vetter, M. L., Amaro, A., & Volger, S. (2014). Nutritional management of type 2 diabetes mellitus and obesity and pharmacologic therapies to facilitate weight loss. Postgrad Med, 126(1), 139-152. https://doi.org/10.3810/pgm.2014.01.2734

Wadden, T. A., Chao, A. M., Machineni, S., Kushner, R., Ard, J., Srivastava, G., Halpern, B., Zhang, S., Chen, J., Bunck, M. C., Ahmad, N. N., & Forrester, T. (2023). Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial. Nature Medicine, 29(11), 2909-2918. https://doi.org/10.1038/s41591-023-02597-w

Weijs, P. J. M. (2025). Protein requirement in obesity. Curr Opin Clin Nutr Metab Care, 28(1), 27-32. https://doi.org/10.1097/mco.0000000000001087

Wharton, S., Calanna, S., Davies, M., Dicker, D., Goldman, B., Lingvay, I., Mosenzon, O., Rubino, D. M., Thomsen, M., Wadden, T. A., & Pedersen, S. D. (2022). Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss. Diabetes Obes Metab, 24(1), 94-105. https://doi.org/10.1111/dom.14551

Wharton, S., Davies, M., Dicker, D., Lingvay, I., Mosenzon, O., Rubino, D. M., & Pedersen, S. D. (2022). Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice. Postgraduate Medicine, 134(1), 14-19. https://doi.org/10.1080/00325481.2021.2002616

Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Gaal, L. F. V., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., & Kushner, R. F. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989-1002. https://doi.org/doi:10.1056/NEJMoa2032183

Wilding, J. P. H., Batterham, R. L., Davies, M., Van Gaal, L. F., Kandler, K., Konakli, K., Lingvay, I., McGowan, B. M., Oral, T. K., Rosenstock, J., Wadden, T. A., Wharton, S., Yokote, K., & Kushner, R. F. (2022). Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab, 24(8), 1553-1564. https://doi.org/10.1111/dom.14725